Burger line Burger line Burger line
Logo Logo Logo
Burger line Burger line Burger line
Sign in
Sign in

AstraZeneca diabetes drug cuts heart risks in major study

LONDON (Reuters) - AstraZeneca said on Monday its diabetes drug Farxiga met a key goal in a major clinical study designed to show the heart-protecting benefits of the medicine.

Haworth projection of dapagliflozin.svg

Diabetics are at increased risk of heart problems, making the cardiovascular (CV) profile of medicines to treat the condition a key focus for doctors and patients.

In the 17,000-patient trial known as Declare, patients on Farxiga achieved a statistically-significant and clinically-important reduction in hospitalization for heart failure or CV death compared with those on placebo, the company said.

There were also fewer major adverse cardiovascular events, although in this case the difference did not reach statistical significance.

Full results from the Declare study will be presented on Nov. 10 at the annual meeting of the American Heart Association.

Farxiga competes with rival diabetes drugs such as Eli Lilly’s Jardiance and Novo Nordisk’s Victoza, which has already shown certain heart benefits.

SEPTEMBER 24, 2018


0
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote

We use "cookies*  to ensure the functionality of our website, recognise your browser or device, learn more about your interests, and provide you with essential features and services and for additional purposes, including:

Recognising you when you sign-in to use our services. This allows us to provide you with product recommendations, display personalised content, and provide other customised features and services.
Keeping track of your specified preferences. You may set your preferences through Your Account..
Keeping track of items stored in your shopping basket and personal cabinet.
Conducting research and diagnostics to improve ChemDiv’s content, products, and services.
Delivering content, including ads, relevant to your interests on ChemDiv’s site
Reporting. This allows us to measure and analyse the performance of our services.

By  cookies you give consent to the processing of your personal data, including transfer to third parties. Further information can be found in our privacy policy.

Accept all cookies